A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

Medically reviewed by Doru Paul, MD Multiple myeloma is a type of blood cancer that develops in plasma cells, a type of white ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...

A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory ...

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...

Discover how ctDNA offers a non-invasive approach to diagnosing and monitoring multiple myeloma, improving risk ...

This study reveals distinct immune subpopulations associated with specific myeloma cell genotypes and highlights the central ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...